Trial · NCT07898501
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Red blood cell contamination of research-only SVF | Baseline (procedure day) | Red blood cell contamination proportion in research-only SVF. |
| Primary | Total nucleated cell count of research-only SVF | Baseline (procedure day) | Number of nucleated cells in research-only SVF. |
| Primary | MSC-like stromal progenitor cell composition | Baseline (procedure day) | Research-only SVF cells with the protocol phenotype CD73+, CD90+, CD146+/CD45-, CD31-. |
| Primary | CD34-positive adipose stromal progenitor cell composition | Baseline (procedure day) | Research-only SVF CD34+ adipose stromal progenitor cells. |
| Primary | Research-only SVF secretome analyte concentrations | Baseline (procedure day) | Individual concentrations of HGF, VEGF-A, IGF-1, IL-1β/IL-1F2, IL-1Ra/IL-1F3, IL-6, IL-10, PGE2, IL-8/CXCL8, MMP-3, MMP-13, and COMP. |
| Primary | Change from baseline in synovial fluid biomarker concentrations at 6 months | Immediately before injection and 6 months after injection | Paired change in each of the same 12 analytes listed in outcome 5. Each analyte is assessed individually. Six-month synovial fluid concentrations are recorded in pg/mL; paired measurements use the same units. |
| Secondary | Change from baseline in pain VAS at 6 months | Baseline and 6 months after injection | Activity-related knee pain VAS, 0-10; higher scores indicate greater pain. |
| Secondary | Change from baseline in WOMAC at 6 months | Baseline and 6 months after injection | WOMAC total score, 0-96, with pain (0-20), stiffness (0-8), and physical function (0-68) subscales. Higher scores indicate worse symptoms or disability. |
| Secondary | Change from baseline in KOOS at 6 months | Baseline and 6 months after injection | KOOS symptoms, pain, activities of daily living, sport/recreation, and knee-related quality-of-life subscales, each 0-100; higher scores indicate better status. Subscales are assessed separately. |
| Secondary | Change from baseline in IKDC subjective score at 6 months | Baseline and 6 months after injection | IKDC subjective score, 0-100; higher scores indicate better function and fewer symptoms. |
| Secondary | Change from baseline in Kellgren-Lawrence grade at 6 months | Baseline and 6 months after injection | Radiographic Kellgren-Lawrence grade; higher grades indicate greater severity. Baseline grade II/III and six-month grades I-IV are recorded in the CRF. |
| Secondary | Change from baseline in knee joint space at 6 months | Baseline and 6 months after injection | Medial and lateral knee joint space widths, recorded separately in millimeters on knee radiographs. |
| Secondary | Change from baseline in osteophytes at 6 months | Baseline and 6 months after injection | Osteophyte severity recorded as absent, mild, moderate, or severe. Changes in grade and worsening are assessed. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07898501/registered